Vofatamab, an anti-FGFR3 antibody, was in three phase I and phase I/II studies for bladder cancer, all of which were terminated, even though FGFR3 seems to be an interesting target, especially for NMIBC. Here, FGFR3 is linked to urinary bladder cancer.